Muscle-Targeted Nanocomposite Therapy Alleviates Age-Related Sarcopenia via Antioxidant and Metabolic Reprogramming.

Liu Z, Shen Z, Lu H, Lu B, Zhang P, Chen W, Huang G, Qu X, Yu Z, Chen F, Zang W

ACS nano30 Dec 2025Cited by 1 (Europe PMC)

PMID41468174DOI10.1021/acsnano.5c18226PepBankPUB-41468174

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MOTS-c.

01AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Efficacy outcome
In cellular and murine models of age-related sarcopenia, the BP-PEG-MOTS‑c nanocomposite alleviated muscle dysfunction.
In plain wordsIn cells and mice with age-related muscle loss, a nanocomposite that contains MOTS‑c and black phosphorus eased muscle weakness.
Peptide
MOTS-c
Outcome
DecreaseMuscle dysfunction
Study
mousen: not reported in source
Age-related sarcopenia
Outcome group
Exercise and physical function · Musculoskeletal
Source sentences
Summary
In cellular and murine models with age-related sarcopenia, BM treatment alleviates muscle dysfunction and muscle loss, concurrently normalizing mitochondrial function and reducing lipid peroxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this pathophysiology, we engineer a muscle-targeted nanocomposite (BP-PEG-MOTS-c, BM) combining mitochondrial-derived peptide MOTS-c with antioxidant black phosphorus nanosheets (BP).
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-4146817401
02AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Efficacy outcome
In cellular and murine models of age-related sarcopenia, the BP-PEG-MOTS‑c nanocomposite alleviated muscle loss.
In plain wordsIn cells and mice with age-related muscle loss, a nanocomposite that contains MOTS‑c and black phosphorus reduced muscle loss.
Peptide
MOTS-c
Outcome
DecreaseMuscle loss
Study
mousen: not reported in source
Age-related sarcopenia
Outcome group
Muscle injury and repair · Musculoskeletal
Source sentences
Summary
In cellular and murine models with age-related sarcopenia, BM treatment alleviates muscle dysfunction and muscle loss, concurrently normalizing mitochondrial function and reducing lipid peroxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this pathophysiology, we engineer a muscle-targeted nanocomposite (BP-PEG-MOTS-c, BM) combining mitochondrial-derived peptide MOTS-c with antioxidant black phosphorus nanosheets (BP).
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-4146817402
03AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Mechanism
In cellular and murine models of age-related sarcopenia, the BP-PEG-MOTS‑c nanocomposite normalized mitochondrial function.
In plain wordsIn cells and mice with age-related muscle loss, the nanocomposite with MOTS‑c and black phosphorus brought mitochondrial function toward normal.
Peptide
MOTS-c
Outcome
Not applicableMitochondrial function
Study
mousen: not reported in source
Age-related sarcopenia
Outcome group
Mitochondrial function · Musculoskeletal
Source sentences
Summary
In cellular and murine models with age-related sarcopenia, BM treatment alleviates muscle dysfunction and muscle loss, concurrently normalizing mitochondrial function and reducing lipid peroxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this pathophysiology, we engineer a muscle-targeted nanocomposite (BP-PEG-MOTS-c, BM) combining mitochondrial-derived peptide MOTS-c with antioxidant black phosphorus nanosheets (BP).
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-4146817403
04AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Mechanism
In cellular and murine models of age-related sarcopenia, the BP-PEG-MOTS‑c nanocomposite reduced lipid peroxidation.
In plain wordsIn cells and mice with age-related muscle loss, the nanocomposite with MOTS‑c and black phosphorus lowered fat-damaging oxidation.
Peptide
MOTS-c
Outcome
DecreaseLipid peroxidation
Study
mousen: not reported in source
Age-related sarcopenia
Outcome group
Oxidative stress · Musculoskeletal
Source sentences
Summary
In cellular and murine models with age-related sarcopenia, BM treatment alleviates muscle dysfunction and muscle loss, concurrently normalizing mitochondrial function and reducing lipid peroxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this pathophysiology, we engineer a muscle-targeted nanocomposite (BP-PEG-MOTS-c, BM) combining mitochondrial-derived peptide MOTS-c with antioxidant black phosphorus nanosheets (BP).
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-4146817404
05AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Mechanism
RNA-seq showed that the nanocomposite activated PI3K/AKT/Nrf2 signaling and suppressed ROS/p38 MAPK signaling.
In plain wordsIn cells and mice with age-related muscle loss, the nanocomposite switched on protective pathways and switched off a stress pathway.
Peptide
MOTS-c
Outcome
MixedPI3K/AKT/Nrf2 and ROS/p38 MAPK signaling
Study
mousen: not reported in source
Age-related sarcopenia
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
Mechanistic profiling via RNA-seq reveals BM's activation of PI3K/AKT/Nrf2 and suppression of ROS/p38 MAPK signaling pathway, mediating antioxidant responses and maintenance of mitochondrial homeostasis.
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-4146817405
06AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Safety outcome
In toxicity assays, the nanocomposite showed superior biocompatibility compared with conventional delivery systems.
In plain wordsIn toxicity tests, the nanocomposite was better tolerated than conventional delivery systems.
Peptide
MOTS-c
Outcome
Not applicableBiocompatibility in toxicity assays
Study
n: not reported in source
Outcome group
Adverse events · Musculoskeletal
Source sentences
Summary
The nanocomposite demonstrats superior biocompatibility in toxicity assays, outperforming conventional delivery systems.
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-4146817406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.